AAAAAA
Results: 1-25/35
Authors:
HAGEMENAS FC
PAPPU A
NEWCOMB KC
ILLINGWORTH DR
Citation: Fc. Hagemenas et al., COMPARATIVE EFFICACIES OF GEMFIBROZIL, SIMVASTATIN AND ATORVASTATIN IN THE TREATMENT OF PATIENTS WITH TYPE-III HYPERLIPIDEMIA, The FASEB journal, 12(4), 1998, pp. 1380-1380
Authors:
ILLINGWORTH DR
Citation: Dr. Illingworth, EFFECTIVENESS OF STATINS IN THE TREATMENT OF FAMILIAL COMBINED HYPERLIPIDEMIA, Atherosclerosis (Amsterdam), 138, 1998, pp. 5-5
Authors:
GORDON BR
KELSEY SF
DAU PC
GOTTO AM
GRAHAM K
ILLINGWORTH DR
ISAACSOHN J
JONES PH
LEITMAN SF
SAAL SD
STEIN EA
STERN TN
TROENDLE A
ZWIENER RJ
Citation: Br. Gordon et al., LONG-TERM EFFECTS OF LOW-DENSITY-LIPOPROTEIN APHERESIS USING AN AUTOMATED DEXTRAN SULFATE CELLULOSE ADSORPTION SYSTEM, The American journal of cardiology, 81(4), 1998, pp. 407-411
Authors:
DUELL PB
CONNOR WE
ILLINGWORTH DR
Citation: Pb. Duell et al., RHABDOMYOLYSIS AFTER TAKING ATORVASTATIN WITH GEMFIBROZIL, The American journal of cardiology, 81(3), 1998, pp. 368-369
Authors:
WEISS SR
KNOPP R
DAVIDSON M
STEIN EA
LASKARZEWSKI P
ILLINGWORTH DR
DUJOVNE C
HUNNINGHAKE D
MELINO MR
MITCHEL YB
Citation: Sr. Weiss et al., EXPANDED DOSES OF SIMVASTATIN - EFFICACY AND SAFETY OF 80 AND 160 MG IN HYPERCHOLESTEROLEMIA, Journal of the American College of Cardiology, 29(2), 1997, pp. 8064-8064
Authors:
RAAL FJ
PILCHER GJ
ILLINGWORTH DR
PAPPU AS
STEIN EA
LASKARZEWSKI P
MITCHEL YB
MELINO MR
Citation: Fj. Raal et al., EXPANDED-DOSE SIMVASTATIN IS EFFECTIVE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, Atherosclerosis, 135(2), 1997, pp. 249-256
Authors:
RAAL FJ
PILCHER GJ
PIETERSE AC
STEIN EA
LASKARZEWSKI P
ILLINGWORTH DR
MELINO MR
MITCHEL YB
Citation: Fj. Raal et al., TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH EXPANDED DOSES OF SIMVASTATIN, Atherosclerosis, 130, 1997, pp. 119-119
Authors:
DAVIDSON MH
STEIN EA
DUJOVNE CA
HUNNINGHAKE DB
WEISS SR
KNOPP RH
ILLINGWORTH DR
MITCHEL YB
MELINO MR
ZUPKIS RV
DOBRINSKA MR
AMIN RD
TOBERT JA
Citation: Mh. Davidson et al., THE EFFICACY AND 6-WEEK TOLERABILITY OF SIMVASTATIN 80 AND 160 MG DAY/, The American journal of cardiology, 79(1), 1997, pp. 38-42
Authors:
DUELL PB
WHEATON DL
ILLINGWORTH DR
CONNER WE
Citation: Pb. Duell et al., DIET-INDUCED, FUNCTIONAL LOW-DENSITY-LIPOPROTEIN RECEPTOR DEFICIENCY IN A HEALTHY-YOUNG MAN, Journal of investigative medicine, 44(1), 1996, pp. 181-181
Authors:
JONES PJH
PAPPU AS
HATCHER L
LI ZC
ILLINGWORTH DR
CONNOR WE
Citation: Pjh. Jones et al., DIETARY-CHOLESTEROL FEEDING SUPPRESSES HUMAN CHOLESTEROL-SYNTHESIS MEASURED BY DEUTERIUM INCORPORATION AND URINARY MEVALONIC ACID LEVELS, Arteriosclerosis, thrombosis, and vascular biology, 16(10), 1996, pp. 1222-1228
Authors:
PAPPU AS
ILLINGWORTH DR
Citation: As. Pappu et Dr. Illingworth, PLASMA CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY IN PATIENTSWITH PRIMARY HYPERCHOLESTEROLEMIA, The FASEB journal, 10(3), 1996, pp. 3178-3178
Authors:
PULLINGER CR
LOVE JA
LIU WQ
HENNESSY LK
GHASSEMZADEH M
NEWCOMB KC
ILLINGWORTH DR
KANE JP
Citation: Cr. Pullinger et al., THE APOLIPOPROTEIN-B Q3405E POLYMORPHISM HAS NO EFFECT ON ITS LOW-DENSITY-LIPOPROTEIN RECEPTOR-BINDING AFFINITY, Human genetics, 98(6), 1996, pp. 678-680
Authors:
ILLINGWORTH DR
Citation: Dr. Illingworth, CARCINOGENICITY OF LIPID-LOWERING DRUGS, JAMA, the journal of the American Medical Association, 275(19), 1996, pp. 1479-1480
Authors:
NEWCOMB KC
ILLINGWORTH DR
BACON SP
LARSEN ML
Citation: Kc. Newcomb et al., THE EFFECT OF HMG-COA REDUCTASE INHIBITORS AND BILE-ACID SEQUESTRANTSON LDL BINDING IN FAMILIAL DEFECTIVE APOLIPOPROTEIN-B100 (FDB), The FASEB journal, 9(3), 1995, pp. 470-470
Authors:
PAPPU AS
ILLINGWORTH DR
HATCHER L
CONNOR WE
Citation: As. Pappu et al., THE INFLUENCE OF DIET AND LOVASTATIN (LOV) ON CHOLESTEROL-SYNTHESIS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH), The FASEB journal, 9(3), 1995, pp. 575-575
Authors:
ILLINGWORTH DR
HATCHER LF
PAPPU AS
NEWCOMB KC
CONNOR WE
Citation: Dr. Illingworth et al., ROLE OF DIETARY-CHOLESTEROL IN THE OPTIMAL DIET FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, Canadian journal of cardiology, 11, 1995, pp. 115-117
Authors:
ILLINGWORTH DR
Citation: Dr. Illingworth, ECONOMICS OF LIPID-LOWERING WITH HMG COA REDUCTASE INHIBITORS, Clinical cardiology, 18(6), 1995, pp. 295
Authors:
MASLEN CL
BABCOCK D
ILLINGWORTH DR
Citation: Cl. Maslen et al., OCCURRENCE OF A MUTATION ASSOCIATED WITH WOLMAN-DISEASE IN A FAMILY WITH CHOLESTERYL ESTER STORAGE DISEASE, Journal of inherited metabolic disease, 18(5), 1995, pp. 620-623
Authors:
STEIN EA
GORMLEY GJ
ILLINGWORTH DR
KWITEROVICH PO
LASKARZEWSKI PM
Citation: Ea. Stein et al., A ONE-YEAR PLACEBO-CONTROLLED TRIAL OF LOVASTATIN IN ADOLESCENT MALESWITH SEVERE FH - LIPID AND SAFETY CHEMISTRY DATA, Circulation, 92(8), 1995, pp. 596-596
Authors:
FRAUNFELDER FW
FRAUNFELDER FT
ILLINGWORTH DR
Citation: Fw. Fraunfelder et al., ADVERSE OCULAR EFFECTS ASSOCIATED WITH NIACIN THERAPY, British journal of ophthalmology, 79(1), 1995, pp. 54-56
Authors:
ILLINGWORTH DR
TOBERT JA
Citation: Dr. Illingworth et Ja. Tobert, A REVIEW OF CLINICAL-TRIALS COMPARING HMG-COA REDUCTASE INHIBITORS, Clinical therapeutics, 16(3), 1994, pp. 366-385
Authors:
ILLINGWORTH DR
Citation: Dr. Illingworth, THERAPEUTIC USE OF LOVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, Clinical therapeutics, 16(1), 1994, pp. 2-26
Authors:
ILLINGWORTH DR
ERKELENS DW
KELLER U
THOMPSON GR
TIKKANEN MJ
Citation: Dr. Illingworth et al., DEFINED DAILY DOSES IN RELATION TO HYPOLIPEMIC EFFICACY OF LOVASTATIN, PRAVASTATIN, AND SIMVASTATIN, Lancet, 343(8912), 1994, pp. 1554-1555
Authors:
LARSEN ML
ILLINGWORTH DR
Citation: Ml. Larsen et Dr. Illingworth, DRUG-TREATMENT OF DYSLIPOPROTEINEMIA, The Medical clinics of North America, 78(1), 1994, pp. 225-245
Authors:
LARSEN ML
ILLINGWORTH DR
OMALLEY JP
Citation: Ml. Larsen et al., COMPARATIVE EFFECTS OF GEMFIBROZIL AND CLOFIBRATE IN TYPE-III HYPERLIPOPROTEINEMIA, Atherosclerosis, 106(2), 1994, pp. 235-240